A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP

Inclusion Criteria: * Patients voluntarily participated in the study and signed informed consent; * Age ≥60 years old, gender unlimited; * ECOG PS ≤2; * Expected survival ≥6 months; * A definitive diagnosis of ITP, including newly diagnosed, chronic, and persistent ITP; * PLT \< 30×109/L for at least two consecutive times with an interval of at least 1 day before medication * Patients with laboratory test results meet the following criteria: a. alanine aminotransferase (ALT) 3.0 x or less normal limit (ULN), aspartate aminotransferase (AST) 3.0 x ULN or less; b. Serum total bilirubin ≤1.5×ULN; c. Serum creatinine ≤1.5×ULN; * The researchers determined that patients could be treated with hexapopal. Exclusion Criteria: * Patients who did not respond to previous treatment with herombopag; * A history of allergy to thrombopoietin receptor agonist (TPO-RA) drugs; * Combined with other important organ dysfunction, such as liver and kidney failure, cardiac insufficiency, etc. * Secondary thrombocytopenia, such as rheumatic immune disease, chronic liver disease, hyperlienism, malignant hematologic disease, bone marrow hematopoietic exhaustion disease (such as AA, MDS), hereditary thrombocytopenia, CVID, drug-induced thrombocytopenia, etc.; * Receive TPO-RA medication within 2 weeks prior to treatment; * Non-steroidal anti-inflammatory drugs (aspirin, salicylate, etc.) and anticoagulants (warfarin, clopidogrel, etc.) should be taken during treatment, which have an impact on platelet function. * There are severe active bleeding symptoms, such as gastrointestinal bleeding, intracranial bleeding, etc. * Severe thrombotic disease, such as transient ischemic attack, myocardial infarction, pulmonary embolism, deep vein thrombosis, and disseminated intravascular coagulation (DIC), occurred within 6 months prior to the screening period; * Have a New York Heart Society (NYHA) Class 3 or 4 congestive heart failure, or have a history of NYHA Class 3/4 congestive heart failure with a left ejection fraction (LVEF) of \< 45% within 4 weeks prior to treatment; * Positive anti-human immunodeficiency virus antibody or anti-treponema pallidum specific antibody; Hepatitis virus positive, such as HBV, HCV, etc. * A history of cirrhosis; * Bone marrow reticulum fiber staining (MF) ≥2 grade; * Have an active infection that is difficult to control; * Have a history of or accompanied by malignant tumors; * Pregnant or lactating women; * Any other conditions that the investigator determines are not suitable for participation in the study.